The clinical care pathways in early-stage lung cancer are changing
The clinical care pathways in early-stage lung c
Benefits of lung cancer mass screening in China
Benefits of lung cancer mass screening in China
Air-pollution–induced lung cancer: defining a targetable link
Air-pollution–induced lung cancer: defining a ta
Updates on immunotherapy-based treatment of stage III/IV disease
Updates on immunotherapy-based treatment of stag
Targeted approaches in the first and later lines: KRASG12C, EGFR, HER2 & angiogenesis
Targeted approaches in the first and later lines
Treatment benefits and outcome determinants in (neo)adjuvant trials
Treatment benefits and outcome determinants in (
Preface – ESMO Lung Cancer 2022
Preface – ESMO Lung Cancer 2022 © ElainePerks2013 -
Checkpoint inhibition: subgroups, combination maintenance and retreatment
Checkpoint inhibition: subgroups, combination ma
Immune-based strategies are raising hope in small-cell tumors
Immune-based strategies are raising hope in smal
Stage I-III disease: surgical and systemic options
Stage I-III disease: surgical and systemic optio
